Today: 15 June 2026
Browse Category

NASDAQ:AMGN 30 December 2025 - 11 June 2026

Dow surges almost 930 points after the bell as oil drops on Iran strike reversal

Dow surges almost 930 points after the bell as oil drops on Iran strike reversal

Dow surges 1.86% to 50,848.38 as oil prices plunge after President Trump cancels planned strikes on Iran, easing geopolitical fears; Honeywell, Boeing, Caterpillar, Nike, and Amgen lead gains, while Chevron and Microsoft lag; Brent crude drops 3.93% to $89.44, but inflation concerns persist with May PPI up 1.1% and final demand prices up 6.5% year-over-year.
11 June 2026
···········
SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

Schwab’s U.S. Dividend Equity ETF (SCHD) increased health care holdings to 18.5% in its annual rebalance, adding Abbott Laboratories and UnitedHealth Group near the top at about 3.8% each. SCHD attracted $4 billion in Q1 as U.S. dividend funds pulled in $24.1 billion, the highest first-quarter inflow in four years. SCHD closed at $30.48 Monday, up 0.13%.
30 March 2026
············
Dow Jones futures tick up as Wall Street braces for retail sales, jobs and CPI

Dow Jones futures tick up as Wall Street braces for retail sales, jobs and CPI

Dow futures rose 45 points to 50,264 early Tuesday after the index closed at a record 50,135.87 on Monday. Investors await U.S. retail sales data at 8:30 a.m. ET, with forecasts at 0.4%, followed by key payroll and inflation reports later this week. Tech stocks led Monday’s rebound, while losses in Amgen and Merck weighed on the Dow. Earnings from major consumer and industrial firms are also due.
10 February 2026
··
Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen shares dropped 1.8% to $377.28 in mid-afternoon trading Monday, weighing on the Dow Jones Industrial Average. The decline followed news of an FDA request to withdraw rare-disease drug Tavneos and a sharp 48% fall in Enbrel sales last quarter. Broader drug stocks lagged while traders awaited key U.S. jobs and inflation data later in the week.
9 February 2026
····
Dow Jones Industrial Average slips under 50,000 as AI shakeout bites; payrolls, CPI loom

Dow Jones Industrial Average slips under 50,000 as AI shakeout bites; payrolls, CPI loom

The Dow Jones fell 133 points to 49,983 in Monday morning trade, slipping below 50,000 after Friday’s record close. The S&P 500 dipped 0.08% and the Nasdaq was flat as investors rotated out of tech and into industrial and defensive stocks. Amgen and Merck together shaved about 79 points from the Dow. Traders await key payrolls and inflation data later this week.
9 February 2026
···
Amgen stock jumps to a 52-week high; here’s what to watch before Monday’s open

Amgen stock jumps to a 52-week high; here’s what to watch before Monday’s open

Amgen shares jumped 4.49% to $384.32 Friday, hitting a 52-week high as the Dow closed above 50,000 for the first time. The move followed strong quarterly results and a $2.52 per share dividend declaration. CVS Caremark will drop Amgen’s Prolia from some preferred lists in April, citing biosimilar competition. Investors await next week’s delayed U.S. jobs and inflation data.
8 February 2026
·
Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen shares surged 8.2% to $366.20 Wednesday after quarterly earnings beat forecasts and the company issued a 2026 outlook above consensus. Investors focused on progress in Amgen’s MariTide obesity program, which could allow less frequent dosing. The company reported Q4 revenue of $9.9 billion and adjusted EPS of $5.29. Amgen plans $2.6 billion in 2026 capital spending and capped share buybacks at $3 billion.
5 February 2026
···
Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen shares fell 0.3% to $341.88 Friday after disclosing plans to end its 2021 partnership with Kyowa Kirin, which will regain global rights to the eczema drug rocatinlimab. Amgen will report fourth-quarter and full-year earnings after markets close Feb. 3, with investors focused on pipeline priorities following the Kyowa Kirin exit.
31 January 2026
····
Amgen stock pulled back after a six-day run — here’s what investors watch next week

Amgen stock pulled back after a six-day run — here’s what investors watch next week

Amgen shares fell 0.7% to $344.75 Friday, ending a six-day winning streak after reaching a 52-week high of $349.98 on Thursday. The stock remains up about 4% for the week. Investors are awaiting the Feb. 3 earnings call for updates on Amgen’s obesity drug pipeline and guidance. The board approved a $2.52 quarterly dividend, payable March 6 to shareholders of record by Feb. 13.
24 January 2026
·
Amgen stock slides into weekend as JPMorgan healthcare conference looms

Amgen stock slides into weekend as JPMorgan healthcare conference looms

Amgen shares fell 1.21% to $326.10 Friday, marking a second straight day of losses as the S&P 500 rose. Trading volume reached about 3.7 million shares. Truist maintained a “hold” rating and slightly raised its price target. Investors are watching next week’s J.P. Morgan Healthcare Conference and Amgen’s Feb. 3 earnings report.
10 January 2026
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen shares rose 3.5% to $341.64 after UBS initiated coverage with a buy rating and a $380 target. The move follows FDA approval of Amneal’s biosimilar rivals to Amgen’s Prolia and Xgeva, which generated $5.3 billion in U.S. sales last year. Amgen also announced an $840 million deal to acquire Dark Blue Therapeutics, adding an early-stage leukemia drug. CEO Robert Bradway will present at the J.P. Morgan Healthcare Conference on Jan. 12.
8 January 2026
···
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
1 2

Stock Market Today

  • Fiserv Appoints Takis Georgakopoulos as CEO, Reaffirms 2026 Outlook
    June 15, 2026, 9:21 AM EDT. Fiserv (NASDAQ: FISV) named Takis Georgakopoulos as its new Chief Executive Officer, effective immediately. Georgakopoulos, who joined Fiserv in 2024, brings over 20 years of experience in payments, technology, AI, and cybersecurity, having previously held roles at J.P. Morgan and McKinsey & Company. He succeeds Mike Lyons, who left to become CEO of Truist Financial Corporation. The company reaffirmed its 2026 outlook amid this leadership change. Fiserv's chairman, Gordon Nixon, expressed confidence in Georgakopoulos's ability to execute strategic plans and optimize shareholder value, emphasizing his role in advancing AI integration and modernizing merchant platforms.

Latest articles

Truist taps Fiserv, PNC alum Michael Lyons as next CEO

Truist taps Fiserv, PNC alum Michael Lyons as next CEO

15 June 2026
Truist Financial named former Fiserv CEO Michael P. Lyons as its next president and CEO, effective Sept. 1, succeeding Bill Rogers in a planned transition at the $549 billion-asset bank, bringing leadership with deep banking and payments experience to one of the largest U.S. commercial banks.
JetZero breaks ground in Greensboro; city’s 10,000-unit housing plan gets noticed

JetZero breaks ground in Greensboro; city’s 10,000-unit housing plan gets noticed

15 June 2026
JetZero breaks ground on an 8-million-square-foot aircraft plant at PTI, launching a $4.7 billion investment with over 14,500 jobs and $1.3 billion in annual payroll impact, as North Carolina commits more than $1.1 billion in incentives and Greensboro races to address a critical housing shortage tied to the project’s massive scale.
Takis Georgakopoulos picked as Fiserv CEO; Mike Lyons joins Truist

Takis Georgakopoulos picked as Fiserv CEO; Mike Lyons joins Truist

15 June 2026
Fiserv surged 1.38% to $53.78 after appointing Takis Georgakopoulos as CEO, replacing Mike Lyons, who resigned to lead Truist; Fiserv reaffirmed its 2026 outlook, projecting 1%-3% organic revenue growth and adjusted EPS of $8.00-$8.30, as investors weighed the abrupt leadership change and continued focus on technology and AI.
Go toTop